Keywords: Bristol-Myers Squibb, Sprycel, CML-CP, Blood cancer, European approval

European Commission clears Bristol-Myers’s Sprycel for additional use in newly-diagnosed CML

Article | 09 December 2010

US drug major Bristol-Myers Squibb (NYSE: BMY) announced yesterday that Sprycel (dasatinib) 100mg once daily received marketing authorization from the ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Bristol-Myers Squibb

Go to company listing

Related Drugs

Sprycel

Go to drug listing